Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.78 |
| ▸ | CA2 | P00918 | 3/20 | 0.78 |
| ▸ | CA7 | P43166 | 3/20 | 0.78 |
| ▸ | CA9 | Q16790 | 3/20 | 0.78 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.54 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | AGER | Q15109 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7153591 | 0.91 | CA1 (0.76) | CA1CA2CA7CA9TSHR | |
| SCHEMBL9661261 | 0.90 | CA1 (0.66) | CA1CA2CA7CA9TSHR | |
| SCHEMBL5333780 | 0.90 | CA1 (0.66) | CA1CA2CA7CA9TSHR | |
| SCHEMBL15764380 | 0.90 | CA1 (0.66) | CA1CA2CA7CA9TSHR | |
| SCHEMBL23258692 | 0.90 | CA1 (0.70) | CA1CA2CA7CA9TSHR | |
| SCHEMBL122306 | 0.90 | CA1 (0.70) | CA1CA2CA7CA9TSHR | |
| SCHEMBL3545404 | 0.90 | CA1 (0.65) | CA1CA2CA7CA9TSHR | |
| SCHEMBL508126 | 0.90 | CA1 (0.70) | CA1CA2CA7CA9TSHR | |
| SCHEMBL218661 | 0.90 | CA1 (0.70) | CA1CA2CA7CA9TSHR | |
| SCHEMBL16269805 | 0.90 | CA1 (0.70) | CA1CA2CA7CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 424 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| EP-0842916-A1 | Bolaform compounds of glycerol, processes for their preparation and their uses | CECA S.A. (FR) | 1998-05-20 | — | — | EP | claimed |
| JP-6072990-A | — | — | None | — | — | JP | disclosed |
| JP-6080608-A | — | — | None | — | — | JP | disclosed |
| JP-6100486-A | — | — | None | — | — | JP | disclosed |
| JP-5320105-A | — | — | None | — | — | JP | disclosed |
| EP-4129062-B1 | METHOD FOR FORMING A PROTECTIVE COATING BY APPLYING FATTY ACID GLYCERIDE COMPOUNDS TO A SURFACE | APEEL TECH INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4704905-A1 | LYMPHATIC SYSTEM-TARGETING COMPOUNDS | Sage Therapeutics, LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260036904-A1 | PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR PRODUCING CURED RELIEF PATTERN, AND SEMICONDUCTOR DEVICE | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2026-02-05 | — | — | US | disclosed |
| US-12539338-B2 | Nano-enabled immunotherapy in cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-03 | — | — | US | disclosed |
| US-4507305-A | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1985-03-26 | — | — | US | disclosed |
| US-4501744-A | Substituted-aza-cytosine compounds and anti-viral uses thereof | ENS BIO LOGICALS INC. (CA) | 1985-02-26 | — | — | US | disclosed |
| EP-0105486-A2 | 1-Monophosphate esters, 1,3-bisphosphate esters and cyclic phosphate esters of 9-(1,3-dihydroxy-2-propoxymethyl)-guanine as antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1984-04-18 | — | — | EP | disclosed |
| EP-0105135-A1 | Substituted 9-(1-0- or 3-0-monosubstituted or 1,3-di-0-substituted 1,3 dihydroxy-2-propoxymethyl) purines as antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1984-04-11 | — | — | EP | disclosed |
| US-4423050-A | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1983-12-27 | — | — | US | disclosed |
| EP-0085424-A2 | Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl)purines as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1983-08-10 | — | — | EP | disclosed |
| EP-0066208-A1 | 9-(1,3-Dihydroxy-2-propoxymethyl)-guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1982-12-08 | — | — | EP | disclosed |
| US-4355032-A | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1982-10-19 | — | — | US | disclosed |
| EP-0049072-A1 | Guanine compounds and their use for the preparation of anti-viral agents | SYNTEX (U.S.A.) INC. (US) | 1982-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539338-B2 | Nano-enabled immunotherapy in cancer | IDO1, IDO2, BID | CA1 458/4885CA2 1517/4885CA7 2885/4885 |
| US-20260036904-A1 | PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR PRODUCING CURED RELIEF PATTERN, AND SEMICONDUCTOR DEVICE | RER1, ASIC1, FRG1 | CA1 193/4885CA2 720/4885CA7 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.